Navidea Biopharmaceuticals Inc. (AMEX:NAVB) finished Friday with a subtraction of $0.0 to close at $0.08, a downside of -1.90 percent. An average of 3,384,200 shares of common stock have been traded in the last five days. There was a fall of -$0.0095 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 3,689,485 shares traded, while the 50-day average volume stands at 8,109,634.
NAVB stock has decreased by -16.67% in the last month. The company shares reached their 1-month lowest point of $0.0626 on 08/07/23. With the stock rallying to its 52-week high on 02/08/23, shares of the company touched a low of $0.06 and a high of $0.39 in 52 weeks. It has reached a new high 4 times so far this year and lost -63.10% or -$0.1325 in price. In spite of this, the price is down -80.13% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Navidea Biopharmaceuticals Inc. (NAVB) stock’s beta is 1.52. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 953.73.
Financial Health
The quick ratio of Navidea Biopharmaceuticals Inc. for the three months ended September 29 was 0.80, and the current ratio was 0.80, indicating that the company is not able to meet its debt obligations. Navidea Biopharmaceuticals Inc.’s EBITDA margin for the year ending September 29 is -21091.77%. Its gross profit as reported stood at -$0.12 million compared to revenue of $66000.0.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Navidea Biopharmaceuticals Inc.’s return on assets was -129.70%.
Earnings Surprise
The company posted a net income of $5.82 million in the quarter, while revenues of -$1.48 million were grew 151.55%. The analyst consensus anticipated Navidea Biopharmaceuticals Inc.’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.08, a 27.30% surprise. For the quarter, EBITDA amounted to -$2.29 million. Shareholders own equity worth $99.83 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Navidea Biopharmaceuticals Inc. (NAVB) price momentum. RSI 9-day as of the close on 25 August was 44.12%, suggesting the stock is Neutral, with historical volatility in this time frame at 171.53%.
As of today, NAVB’s price is $0.0824 -10.92% or -$0.0095 from its 5-day moving average. NAVB is currently trading -18.42% lower than its 20-day SMA and -69.01% lower than its 100-day SMA. However, the stock’s current price level is -4.67% below the SMA50 and -69.00% below the SMA200.
The stochastic %K and %D were 34.57% and 42.79%, respectively, and the average true range (ATR) was 0.0116. With the 14-day stochastic at 26.87% and the average true range at 0.0119, the RSI (14) stands at 44.48%. The stock has reached -0.0044 on the 9-day MACD Oscillator while the 14-day reading was at -0.0004.
Analyst Ratings
Aegis Capital reiterated its a Hold rating on Navidea Biopharmaceuticals Inc. (AMEX: NAVB), but raised their price target to $3, indicating a potential price increase of 97.33% for the stock. The consensus rating for Navidea Biopharmaceuticals Inc. (NAVB) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NAVB, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is NAVB’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $8.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Navidea Biopharmaceuticals Inc. (NAVB) stock is $8.00.
